PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.42%
Negative revenue growth while MRVL stands at 4.29%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-0.96%
Negative gross profit growth while MRVL is at 3.82%. Joel Greenblatt would examine cost competitiveness or demand decline.
-0.65%
Negative EBIT growth while MRVL is at 8.09%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-2.38%
Negative operating income growth while MRVL is at 15.99%. Joel Greenblatt would press for urgent turnaround measures.
21.82%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
14.29%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
15.00%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
4.86%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
5.55%
Diluted share count expanding well above MRVL's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
-7.44%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
71.52%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
221.43%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
2.56%
10Y revenue/share CAGR under 50% of MRVL's 56.20%. Michael Burry would suspect a lasting competitive disadvantage.
-18.47%
Negative 5Y CAGR while MRVL stands at 109.65%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-10.52%
Negative 3Y CAGR while MRVL stands at 25.49%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
17.47%
Below 50% of MRVL's 45.44%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
212.82%
3Y OCF/share CAGR above 1.5x MRVL's 63.72%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
309.18%
Below 50% of MRVL's 653.69%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
90.17%
Below 50% of MRVL's 220.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
346.95%
3Y net income/share CAGR above 1.5x MRVL's 202.86%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
112.72%
10Y equity/share CAGR above 1.5x MRVL's 54.87%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
143.50%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
73.87%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
74.53%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
31.98%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
-9.70%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
16.07%
AR growth well above MRVL's 11.24%. Michael Burry fears inflated revenue or higher default risk in the near future.
9.29%
Inventory growth well above MRVL's 4.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
19.47%
Positive asset growth while MRVL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
12.42%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
16.35%
Debt growth far above MRVL's 3.89%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-4.11%
Our R&D shrinks while MRVL invests at 1.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
10.71%
We expand SG&A while MRVL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.